RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer comboCurrently Roche's CD3 bispecific for lymphoma drug Lunsumio (monsunetuzumab) is an off-the-shelf antibody that has been given conditional approval in Europe and will be a contender with CAR-T therapy in liquid cancers. Lunsumio can be used alone or in combination with its checkpoint inhibitor atezolizumab.
Pfizer's bispecific elranatamab is an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody in development for the treatment of multiple myeloma (MM).
Abbvie is another Big Pharma company involved in the development of CD3 bispecifics.
A bispecific antibody approach may allow for binding to targets on malignant cells, while simultaneously binding to CD3 on T cells, inducing activation and cytotoxic activity of T cells enabling lysis of target-expressing malignant cells.
ONCY's oncolytic virus facilitates CD3 binding while it "primes" the immune system for both an innate and adaptive immune response to the tumor cells and models the tumor microenvironment (TME) towards T-cell activation and the minimization of T-cell exhaustion.